| abstract |
Fibromyalgia is a disease in which the development of therapeutic drugs is difficult because the etiology and the mechanism of development have not been elucidated. When salazosulfapyridine, a therapeutic agent for rheumatism, was administered to fibromyalgia patients, it was unexpectedly effective for treating fibromyalgia without rheumatoid factors or immune abnormalities. It was effective in alleviating the pain of partial inflammation. Furthermore, it was effective in relieving pain of fibromyalgia as well as ameliorating tendon adhesion inflammation. In cases where salazosulfapyridine alone was less effective, the combination of salazosulfapyridine and corticosteroids or non-steroidal anti-inflammatory agents increased the therapeutic effect of salazosulfapyridine. |